See our case study or download our white paper!
Explicyte is planning a new in vivo shuttle session by mid-November that can be held on a series of syngeneic tumor mouse models. This shuttle session can focus either on only an in vivo efficacy monitoring or on a comprehensive assessment relying on a multiparametric platform strategy for a deeper understanding of how a cancer therapy performs.
Immunotherapy-based anti-cancer strategies such as immune checkpoint inhibitors promote antitumor immune response driven by themobilization of effector immune cell activity and/or reversal of immunosuppressive mechanisms.
Explicyte was pleased to participate in the AACR Virtual Annual Meeting to get breakthroughs in Immuno-Oncology and to present our posters featuring our capacities that support drug discovery.
By setting new facilities within the cancer center “Institut Bergonié”, Explicyte strengthens its development towards clinical translational research, to provide new services based on multiparametric experimental biomarker analysis, for target identification and monitoring of the immune response in the context of clinical trials.
Explicyte and Institut Bergonié have entered into a collaboration to conjointly drive a translational research program aiming at identifying resistance mechanisms to immune checkpoint inhibitors in cancer patients.
We will be attending the AACR Annual Meeting in Atlanta, from March 29 to April 3, 2019. We will be glad to take this opportunity to meet you there, describe our service offerings and approach your research projects.
Our newly validated M2 suppression assay is specifically designed to assess new immunotherapeutics for their modulatory activity on the phenotype and function of M2 macrophages.
Syngeneic tumor models are becoming invaluable for preclinical development and evaluation of immuno-based therapies. They are primordial for tumor model characterization and selection of the appropriate ones, for target validation, drug development, and assessment of the efficacy potential of drug candidates.
Explicyte is planning a new in vivo shuttle session by early March, thereby providing an opportunity to cost-effectively assess your drug candidates in our well-suited immunocompetent syngeneic subcutaneously-implanted tumor models.
Explicyte set up and validated a robust real-time neutrophil migration assay, which allows for time-lapse monitoring and analysis of chemotactic driven neutrophil migration across an optically clear filter membrane.
Eurostars, a European joint programme, co-funded from the national budgets of several EUREKA countries and by the European Union through Horizon 2020 has awarded, through a highly-competitive selection process, the Project “A novel modified natural killer (NK) cell immunotherapy for the treatment of solid tumours” – MODIFY-NK.